Form 4: Sonnet BioTherapeutics Director Albert Dyrness Acquires Restricted Stock Units
SEC Form 4 Filing
Director Albert Dyrness of Sonnet BioTherapeutics Holdings, Inc. was granted 373 restricted stock units on December 11, 2023, which will vest on January 1, 2025.
Summary
- Albert Dyrness, a director at Sonnet BioTherapeutics Holdings, Inc., received 373 restricted stock units on December 11, 2023.
- These restricted stock units will be settled in shares of common stock.
- The units will vest 100% on January 1, 2025.
- The reported holdings include unvested restricted stock units.
- All share amounts reflect the company's 1:22 reverse stock split effective August 31, 2023, and a 1:8 reverse stock split effective September 30, 2024.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction of stock grants to a director, which is generally a neutral to slightly positive event as it aligns interests. The reverse stock splits are not ideal but are not uncommon for companies in this sector.
Positives
- The grant of restricted stock units to a director aligns their interests with the company's long-term performance.
Industry Context
This is a standard SEC Form 4 filing, which is common for publicly traded companies when there are changes in beneficial ownership by directors or officers. The grant of restricted stock units is a typical form of equity compensation.
Comparison to Industry Standards
- The use of restricted stock units as compensation is a common practice among publicly traded companies, particularly in the biotech sector.
- The vesting schedule of 100% after just over a year is fairly standard, designed to incentivize long-term commitment from the director.
- Reverse stock splits are often used by companies to maintain listing requirements or to increase the share price, which is not uncommon in the biotech industry.
Stakeholder Impact
- The grant of restricted stock units to a director may be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 12/11/2023 | Date of the restricted stock unit grant to Albert Dyrness. |
| 08/31/2023 | Effective date of the 1:22 reverse stock split. |
| 09/30/2024 | Effective date of the 1:8 reverse stock split. |
| 01/01/2025 | Vesting date for the restricted stock units. |
| 12/05/2024 | Date of signature for the form. |
Keywords
restricted stock units, stock grant, insider trading, beneficial ownership, reverse stock split, Sonnet BioTherapeutics, director, equity compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.